Patient P-03037
Therapy response
Declining
Tolerance
Stable
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
87%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S14
- Day 39 NP-02 recommended — Dietary Support Protocol NP-02
- Day 40 Patient accepted — Started NP-02 in the companion
- Day 50 GI symptom burden −23% vs expected — Dietary Support Protocol NP-02
- Day 56 Tolerance state changed — Unstable → Improving
- Day 63 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 63 GI-04 recommended — GI Support Protocol GI-04
- Day 64 Patient accepted — Started GI-04 in the companion
- Day 72 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 63.
Primary contributors, last 14 days
- GI instability+9
- Nutritional resilience-4
- Treatment adherence-4
What helped?
- Dietary Support Protocol NP-02Day 39Result: symptom burden −23%
- GI Support Protocol GI-04Day 63Result: no meaningful change
LIFE OS recommendation
Supportive Compound SC-12
78%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 88% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑95
- DNACYP2D6 poor metabolizer → higher exposure
- DNADPYD *2A → slower clearance
- BloodToxicity index 43
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 33/100
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 57
- Autonomic recovery ↓45
- WearableResting HR 77 bpm
- Wearable2,020 steps/day
- Mucosal barrier integrity ↓20
- Daily logGI symptom score 66 and rising
DNA
Fictional pharmacogenomic panel
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.2 · butyrate capacity 33/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 39 ms
- Sleep
- 6.7 h
- Steps
- 3,011
- Resting HR
- 79 bpm
Daily log: GI score 66, nutritional resilience 39, adherence 38.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03323 | 57% | S14 | GI-04 | improved | 48 |
| P-03430 | 49% | S14 | SC-12 | improved | 45 |
| P-03049 | 48% | S14 | GI-04 | improved | 49 |
| P-03293 | 48% | S14 | GI-04 | no change | 41 |
| P-03460 | 47% | S11 | SC-12 | improved | 46 |
| P-03413 | 46% | S14 | ME-01 | improved | 48 |
| P-03390 | 45% | S14 | ME-01 | improved | 41 |
| P-03341 | 44% | S14 | NP-02 | improved | 49 |
| P-03345 | 41% | S14 | SC-12 | improved | 56 |
| P-03090 | 40% | S02 | GI-04 | improved | 48 |
| P-03226 | 40% | S05 | GI-04 | improved | 43 |
| P-03030 | 39% | S14 | NP-02 | improved | 43 |